

1 **Combination of ferric ammonium citrate with cytokines involved in apoptosis and insulin**  
2 **secretion of human pancreatic beta cells related to diabetes in thalassemia**

3  
4 Patchara Rattanaporn,<sup>1,2</sup> Sissades Tongsimma,<sup>3,4</sup> Thomas Madrup-Poulsen,<sup>5</sup> Saovaros Svasti,<sup>2,6</sup>  
5 Dalina Tanyong<sup>1\*</sup>

6 \*Corresponding author

7  
8 <sup>1</sup>Department of Clinical Microscopic, Faculty of Medical Technology, Mahidol University,  
9 Nakhon Pathom, Thailand

10 <sup>2</sup>Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon  
11 Pathom, Thailand

12 <sup>3</sup>National Center for Genetics Engineering and Biotechnology, National Science and Technology  
13 Development Agency, Pathum Thani, Thailand

14 <sup>4</sup>National Biobank of Thailand, National Science and Technology Development Agency, Pathum  
15 Thani, Thailand

16 <sup>5</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of  
17 Copenhagen, Copenhagen, Denmark

18 <sup>6</sup>Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.

19

20 **CORRESPONDING AUTHOR:**

21 Dalina Tanyong, Ph.D.  
22 Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University,  
23 999 Phutthamonthon 4 Road, Salaya, Phutthamonthon, Nakhon Pathom 73170, Thailand. Tel: +66  
24 (2) 441 4371-5#2202, Fax: +66 (2) 441 4380. E-mail: dalina.itc@mahidol.ac.th

25

26

27

28 **ABSTRACT**

29 **Background:** Diabetes mellitus is a common complication found in  $\beta$ -thalassemia patients. The  
30 mechanism of diabetes mellitus in  $\beta$ -thalassemia patients is still unclear, but it may arise from iron

Deleted: <sup>4</sup>

Deleted: <sup>5</sup>

Deleted: \*

Deleted: Co-c

Deleted: Biostatistics and Informatics Laboratory, Genome Institute, National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani, Thailand

Deleted: <sup>4</sup>

Deleted: <sup>5</sup>

Deleted: or  
Saovaros Svasti, Ph.D.  
Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, 25/25 Phutthamonthon 4 Road, Salaya, Nakhon Pathom 73170, Thailand. Tel: +66-2889-2557, Fax: +66-2889-2559, E-mail: saovaros.sva@mahidol.ac.th, stssv@yahoo.com

Commented [GG1]: Please minimize abbreviations in abstract

Deleted: (DM)

Deleted: DM

Deleted: could be

Deleted: an

51 overload and increase of cytokines, such as interleukin1- $\beta$  (IL-1 $\beta$ ) and tumor necrosis factor- $\alpha$   
52 (TNF- $\alpha$ ). The objective of this study was to study the interaction between ferric ammonium citrate  
53 (FAC) and cytokines, IL-1 $\beta$  and TNF- $\alpha$ , on 1.1B4 human pancreatic  $\beta$ -cell line.

54 **Methods:** The effect of the combination of FAC and cytokines on cell viability was studied by  
55 MTT assay. Insulin secretion was assessed by enzyme-linked immunosorbent assay (ELISA).  
56 Reactive oxygen species (ROS) and cell apoptosis in normal and high glucose conditions were  
57 determined by flow cytometry. In addition, gene expression of apoptosis and antioxidant markers  
58 such as glutathione peroxidase 1 (GPX1) and superoxide dismutase 2 (SOD2), and insulin  
59 secretory function were studied by real-time polymerase chain reaction.

60 **Results:** The findings revealed that FAC exposure resulted in decreased cell viability and insulin-  
61 release, and the induction of ROS and apoptosis in pancreatic cells. Interestingly, a combination  
62 of FAC and cytokines had an additive effect on SOD2 antioxidants' genes expression and  
63 endoplasmic reticulum stress. In addition, it reduced the insulin secretion genes expression;  
64 insulin, glucose kinase, protein convertase 1, and protein convertase 2. Moreover, the highest ROS  
65 and the lowest insulin secretion were found in FAC combined with IL-1 $\beta$  and TNF- $\alpha$  in the high-  
66 glucose condition of human pancreatic beta cell, which could be involved in the mechanism of  
67 DM development in  $\beta$ -thalassemia patients.

68  
69 **Keywords:** FAC, cytokines, pancreatic beta cell, thalassemia, diabetes

## 71 INTRODUCTION

72 One of the hereditary blood disorders resulting from a defect in  $\beta$ -globin chain  
73 synthesis is  $\beta$ -thalassemia, which is caused by point mutation or, more rarely, deletion of the  $\beta$ -

Deleted: some

Deleted: effect of

Deleted: the

Deleted: The r

Deleted: er

Deleted: ,

Deleted: ;

Deleted: (Real-time PCR)

Deleted: the

Deleted: of

Deleted: (ER)

Deleted: (INS)

Deleted: (GCK)

Deleted: (PSCK1),

Deleted: (PSCK2)

Deleted:

90 globin gene (*Galanello and Origa 2010*). These defects cause an imbalance between  $\alpha$  and  $\beta$ -  
91 globin chains leading to ineffective erythropoiesis (IE) chronic hemolytic anemia. Extramedullary  
92 erythropoiesis is caused by  $\beta$ -thalassemia, which leads to bone deformities and  
93 hepatosplenomegaly. Many complications were found such as heart failure, cirrhosis, and  
94 endocrine complications including DM (*Weatherall 2003*). The prevalence of DM has been  
95 reported by up to 40% in  $\beta$ -thalassemia patients (*Ghergherehchi and Habibzadeh 2015; Li et al.*  
96 *2014; Liang et al. 2017; Metwalley and El-Saied 2014*).

Commented [GG2]: Please define here not in abstract – same of other abbreviations

97 Patients with  $\beta$ -thalassemia and DM have a higher risk of cardiovascular complications,  
98 (*Pepe et al. 2013*). However, the mechanism of DM in  $\beta$ -thalassemia patients is still unclear.  
99 Several mechanisms involved in DM development in  $\beta$ -thalassemia patients were reported  
100 including insulin resistance, hepatic dysfunction, and insulin deficiency resulting from  $\beta$ -cell  
101 damage or apoptosis (*Noetzli et al. 2012; Ghergherehchi and Habibzadeh 2015; Li et al. 2014*).  
102 However, there is no report linking iron and those mechanisms in  $\beta$ -thalassemia patients.

Deleted: ,

Deleted: which are the cause of mortality and morbidity in these patients as well as DM in the general population

103 Pancreatic  $\beta$ -cell damage is caused by many factors such as hyperglycemia, ROS,  
104 pharmacological factors, environmental toxicity factors, tumors, chronic pancreatitis, infections,  
105 inflammation, and autoimmunity. ROS caused by iron leads to damaged cells via the Fenton  
106 reaction. Iron is thought to cause cell death through ROS-dependent and -independent mechanisms  
107 (*Dixon and Stockwell 2014; Bogdan et al. 2016*). Although the iron metabolism in pancreatic  $\beta$ -  
108 cells is still unclear, it is believed that pancreatic islet cells are susceptible to oxidative damage  
109 because they express low levels of antioxidants (*Tiedge et al. 1997*). One study of iron regulation  
110 in pancreatic islet cells reported that high expression of divalent metal transporter (DMT1) caused  
111 more iron deposits in pancreatic cells than other cells (*Andrews 1999*).

Deleted: of the

Deleted: between

Deleted: through

Deleted: s

Deleted: not only

Deleted: but also

Deleted: ROS

Deleted: but

Deleted: ed

Deleted: The

Deleted: was

Deleted: .

Deleted: The result has showed

128 In  $\beta$ -thalassemia patients, iron might not be the only factor that causes  $\beta$ -cell damage.

129 Increased levels of inflammatory cytokines have been reported in  $\beta$ -thalassemia patients,  
130 especially TNF- $\alpha$  and IL-1 $\beta$ , with mean levels 3- and 28-times higher than normal controls,  
131 respectively (Wanachiwanawin *et al.* 1999). These might cause  $\beta$ -cell damage through apoptosis  
132 signaling pathways in  $\beta$ -thalassemia patients. In addition, cytokines, especially IL-1 $\beta$ , also have  
133 the potential to increase intracellular iron and ROS, which cause apoptosis as has been described  
134 in insulin-producing cells (Hansen *et al.* 2012). Therefore, the increase of both iron and cytokines  
135 might be an important mechanism of DM in  $\beta$ -thalassemia patients. Here, the combined effect of  
136 iron and cytokines on the human pancreatic  $\beta$ -cell line is examined.

137

## 138 MATERIALS & METHODS

### 139 Pancreatic cell culture

140 The human pancreatic  $\beta$ -cell line 1.1B4 was generated by electrofusion of freshly isolated human  
141 pancreatic beta cells and the human PANC-1 epithelial cell line. It showed glucose sensitivity and  
142 responsiveness to known modulators of insulin secretion (McCluskey *et al.* 2011). The 1.1B4 cells  
143 passage 28 (ECACC Cat. No. 10012801) were routinely cultured in pre-warmed RPMI640 culture  
144 medium with L-glutamine containing 11.1 mM glucose (Thermo Fisher Scientific, Waltham, MA,  
145 USA) supplemented with 10 % (v/v) (fetal bovine serum (Merck, Burlington, MA, USA) (and 10  
146 U/ml penicillin and 0.1 g/l streptomycin) Thermo Fisher Scientific (at 37 °C in 5 %CO<sub>2</sub>).

### 147 1.1B4 cell treatment with FAC, cytokines and high glucose

148 The 1.1B4 cells were plated on six well plates with or without high glucose condition (22.2 mM  
149 glucose) (Vasu *et al.* 2013) and allowed to attach into cell plates for 24 hours. Then, they were

Deleted: The i

Deleted: was

Deleted: . The

Deleted: of TNF- $\alpha$  and IL-1 $\beta$  in patients were

Deleted: 28

Deleted: had

Deleted: was the

Deleted: of cell

Deleted: and was observed

Deleted: the

160 treated with different concentrations of FAC (Merck) or IL-1 $\beta$  or TNF- $\alpha$  (Cell Signaling  
161 Technology, Danvers, MA, USA) for 12 and 24 hours.

162 **Cell viability analysis by MTT assay**

163 MTT assay (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) (Thermo Fisher  
164 Scientific) was used to compare the effect of FAC, IL-1 $\beta$ , and TNF- $\alpha$  on cell viability. The 1.1B4  
165 cells were plated on 96 well plates and allowed to attach plates for 24 hours. After the treatment,  
166 the culture medium was removed, and 100  $\mu$ l of culture medium was added. Then, ten microliters  
167 of 12mM MTT was added and incubated for four hours at 37 $^{\circ}$ C. Finally, 85  $\mu$ L MTT-containing  
168 medium and 50  $\mu$ l DMSO was added to each well and analyzed at 540 nm by a SpectraMax 200  
169 (Molecular Device, San Jose, CA, USA).

170 **Analysis of intracellular ROS by flow cytometer**

171 Intracellular ROS was detected by '2, - '7 Dichlorodihydrofluorescein diacetate (DCFH-DA)  
172 (Merck); the cells were trypsinized and washed twice with Ca $^{2+}$  and Mg $^{2+}$ -free Dulbecco's  
173 phosphate buffer saline, then transferred to *polypropylene (PP) tube*. Then 0.05mg/mL of DCFH-  
174 DA was added into the tube and incubated for 15 minutes at 37 $^{\circ}$ C, %5 CO $_2$ . The fluorescence  
175 signal was detected by a fluorescence-activated cell sorting (FACS) Canto flow cytometer (BD  
176 Biosciences, San Jose, CA, USA) and was analyzed by FACSDiva software (BD Biosciences).

177 **Analysis of apoptotic cells by flow cytometer**

178 The apoptosis cells were detected using Annexin V :FITC Apoptosis Detection Kit I (BD  
179 Biosciences). The cells were washed and incubated with fluorescein isothiocyanate (FITC- (  
180 conjugated annexin V (AnV) and propidium iodide (PI) at room temperature for 15 minutes .  
181 Fluorescence was detected by a FACSCanto flow cytometer and analyzed with FACSDiva  
182 software (BD Biosciences).

### Gene expression by RT-qPCR

Total RNA was extracted from 1.1B4 cells using TRIzol reagent (Invitrogen, Carlsbad, MA, USA). (After the conversion of 5 µg of total RNA to cDNA using RevertAid kit (Thermo Fisher Scientific) (following the manufacturer's instructions, the qPCR was performed using SYBR green. The Select Master Mix for CFX (Applied Biosystem, CA, USA) was used for RT-qPCR, through specific primers (supplement table), and run on CFX96 Touch Real-Time PCR (Bio-Rad, CA, USA). (The level of target gene expression was normalized against *ATCB* expression. The mRNA fold change was calculated using the  $2^{-\Delta\Delta Ct}$  method, with the values expressed as fold change relative to the untreated control.

### Insulin measurement by ELISA

The 1.1B4 cell was treated with FAC alone, cytokine (IL-1β or TNF-α alone), two cytokines (IL-1β+TNF-α), FAC combined with each cytokine (FAC+IL-1β or TNF-α), and FAC combined with both cytokines (FAC+IL-1β+TNF-α) for 24 hours. Then, insulin secretion was assayed by ELISA using the human insulin ELISA kit (Merck), according to the manufacturer's protocol.

### Statistical analysis

The results were analyzed by one-way and two-way analysis of variance (ANOVA) and presented in mean±SEM of three independent experiments. The difference in results was considered significant when  $p < 0.05$ .

## RESULTS

### 1. FAC induce ROS production, reduce cell viability, and decrease insulin expression of pancreatic β-cell

205 The accumulated iron in  $\beta$ -cell islets might promote ROS levels and cell apoptosis  
206 leading to a decrease in insulin production. The cellular ROS levels and cytotoxic effects of iron  
207 were first examined in pancreatic beta cells. FAC (0.1-15 mM) increased ROS levels in a dose-  
208 dependent manner ( $P < 0.05$ ) (Figure 1A). In addition, FAC induced pancreatic cell apoptosis and  
209 reduced cell viability in a dose- and time-dependent manner (Figure 1B and 1G). The highest ROS  
210 (MFI  $1,375 \pm 64.26$ ) and apoptosis (40%) were found in 15 mM FAC-treated cells at 24 hours  
211 (Figure 1A and 1B). Expression of apoptotic regulatory proteins include *BAX*, *BCL2* and *STAT1*  
212 were assessed to study the effect of FAC on  $\beta$ -cell apoptosis. In the 1.1B4 cells treated with 8 mM  
213 FAC the *BAX* were up-regulated at 12h and down-regulated at 24h while *BCL2* was down-  
214 regulated at 12h and 24 h (Figure 1D, 1E and 1F). The lowest cell viability (40%,  $p < 0.001$ ) was  
215 found in cells treated with 10 and 15 mM FAC for 24 hours (Figure 1G).

216 Insulin expression and secretion were assessed to study the effect of FAC on  $\beta$ -cell  
217 function. In the 1.1B4 cells treated with 8 mM FAC the insulin (*INS*) expression and insulin level  
218 decreased in a time-dependent manner (Figure 1H and 1I).

## 219 2. Combination of FAC and cytokines induce ROS production, apoptosis, and reduces 220 insulin expression of pancreatic $\beta$ -cells

222 Cytokine activates the production of ROS and reduction of insulin secretion which lead to diabetes.  
223 The effect of FAC combined with cytokines on pancreatic  $\beta$ -cells was observed. Cells were treated  
224 with IL-1 $\beta$  alone, TNF- $\alpha$  alone, IL-1 $\beta$  combined with TNF- $\alpha$ , FAC alone, and FAC combined with  
225 IL-1 $\beta$ , FAC combined with TNF- $\alpha$ , and FAC combined with IL-1 $\beta$  and TNF- $\alpha$  for 24 hours. The  
226 results showed that ROS and percentage of apoptosis increased but had not significantly different  
227 compared between FAC with cytokines and FAC alone (Figure 2A and 2B). Insulin secretion and

Deleted: C

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: C

Deleted: D

Deleted: E

*INS* expression was reduced in FAC combined with IL-1 $\beta$  or TNF- $\alpha$  compared with FAC alone (Figure 2C and 2D).

The effect of 22.2 mM high glucose was also investigated in 1.1B4 cells, cell viability of pancreatic cell treated with cytokines with FAC was lower than in a normal glucose condition. The lowest cell viability was found in FAC combined with IL-1 $\beta$  and TNF- $\alpha$  in a high-glucose condition (Figure 3A). In addition, the highest ROS was found in FAC combined with IL-1 $\beta$  and TNF- $\alpha$  in the high-glucose condition (Figure 3B). Apoptosis of pancreatic cells in the high-glucose condition was higher than in the normal glucose condition. Interestingly, the highest apoptosis (Figure 3C) ↓lowest insulin secretion (Figure 3D) and lowest *INS* expression were found in FAC combined with IL-1 $\beta$  and TNF- $\alpha$  in the high-glucose condition (Figure 3E).

### **3. FAC combined with IL -1 $\beta$ and TNF - $\alpha$ decrease secretory function genes through antioxidant defense, apoptosis, and ER stress.**

From these results showed that iron (FAC) and cytokines reduce insulin secretion capacity, this evidence was examined by measuring the expression of genes involved in antioxidant defense, apoptosis pathways, ER stress, and secretory function (Figure 3). Two important antioxidant genes in the pancreas, including superoxide dismutase 2 (*SOD2*) and glutathione peroxidase 1 (*GPX.1*) were measured. The results showed that the highest *SOD2* expression was found in FAC combined with TNF- $\alpha$  alone and FAC combined with IL-1 $\beta$  and TNF- $\alpha$ . In addition, apoptosis-related genes, including B-cell lymphoma 2 (*BCL2*), Nuclear factor- $\kappa$ B (*NF $\kappa$ B*), and signal transducer and activator of transcription 1 (*STAT1*) were studied. The results showed that the expression of *BCL2*, *NF $\kappa$ B*, and *STAT1* was decreased (Figure 3C–3E). Gene expressions of Heat Shock Protein Family

**Deleted:** and the

**Formatted:** Font: Italic



256 A (Hsp70) Member 4 (*HSPA4*) and Heat Shock Protein Family A (Hsp70) Member 5 (*HSPA5*),  
257 ER stress marker genes, were analyzed. The highest gene expression of *HSPA4* was shown in FAC  
258 combined with both cytokines. However, the gene expression of *HSPA5* was decreased (Figure 3F  
259 and 3G). Moreover, insulin-secretion related genes including glucose kinase (*GCK*), proprotein  
260 convertase subtilisin/kexin type 1 (*PCSK1*), and proprotein convertase subtilisin/kexin type 2  
261 (*PCSK2*) were determined. The expressions of these genes were decreased more than two times in  
262 FAC treated alone and in combination with cytokines (Figure 4H–4J).

## 263 Discussion

264 DM is commonly found in  $\beta$ -thalassemia patients. The overload of iron and the increase  
265 of cytokines may affect the  $\beta$ -cell function and insulin secretion capacity, which leads to DM  
266 (Wanachiwanawin *et al.* 1999). However, the mechanism of DM in thalassemia is still unclear.  
267 The purpose of this research is to study the effect of FAC combined with cytokines IL-1 $\beta$  and  
268 TNF- $\alpha$  on 1.1B4 in the human pancreatic islet cell line.

269 Firstly, we found that iron exposure resulted in a reduction of cell viability, induction  
270 of ROS, and increasing of apoptosis in a dose-dependent manner in 1.1B4 cells that have been  
271 previously reported in other types of cell line such as HH4, human hematopoietic  
272 cells/mesenchymal cells, MC3T3-E1 cells, and MG-63 cells through different mechanisms (Li *et*  
273 *al.* 2016; Lu *et al.* 2013; Doyard *et al.* 2012; Yang *et al.* 2017; Ke *et al.* 2017). Many reports have  
274 been demonstrated that iron overload lead to increasing intracellular ROS and caused the cell  
275 damage, which is concomitant with our results. Moreover, our results showed the reduction of  
276 *INS* expression and insulin secretion that might be affected by ROS induced by FAC, which finally  
277 caused the  $\beta$ -cell damage. FAC was previously used to induce the excess intracellular iron and

Deleted: FAC

cause increasing of ROS affected insulin secretion in Rat insulinoma pancreatic  $\beta$ -cells (RINm5F) as a model of pancreatic iron overload in  $\beta$ -thalassemia patients (Koonyosying et al. 2019).

The toxic effects of cytokines was studied but the mechanism or pathway underlying those effects in pancreatic  $\beta$ -cell is still unclear. Numerous studies whose findings reported that short-term treatment with cytokines such as IL-1 $\beta$ , TNF- $\alpha$ , and interferon  $\gamma$  (IFN- $\gamma$ ), alone or in combination could induce apoptosis of islet cells and dysfunction of pancreatic  $\beta$ -cells to release insulin (Vasu et al. 2014; Wang, Guan, and Yang 2010), are concomitant with our results.

Interestingly,  $\beta$ -thalassemia patients with iron overloading had high levels of these cytokines and high percentage of apoptosis. The iron and cytokines-induced apoptosis might be the cause of  $\beta$ -cell dysfunction and DM development in these patients. From our results, FAC combined with IL-1 $\beta$  and TNF- $\alpha$  had additive effect on reducing the *INS* expression, inducing *SOD2* antioxidants' genes expression and activate endoplasmic reticulum (ER) stress. The increasing of ROS in FAC combined with IL-1 $\beta$  and TNF- $\alpha$  induced the expression of antioxidant *SOD2* have been reported (Wang et al. 2018). In addition, the induction of *SOD2* expression by cytokines was reported (Vasu et al. 2014). Moreover, the result revealed that the *HSPA4* heat shock 70 kDa protein 4 genes responded to the activation of oxidative stress, protein-folding, and secretion demands that can be found in hyperglycemia (Berchtold et al. 2016). Jacob and co-workers found that 100 pg/ml of IL-1 $\beta$  induced divalent metal transporter 1 (DMT1) expression and caused increasing of ROS and activating apoptosis pathway in pancreatic islets cells (Hansen et al. 2012). This information is not consistent with our results that ROS and apoptosis in FAC combined with IL-1 $\beta$  and/or TNF- $\alpha$  were not significantly different from FAC treated alone.

Iron-induced ROS can activate ferroptosis which might be the possible mechanism of pancreatic  $\beta$ -cell damage in our study. It is a non-apoptosis cell death is induced by the small

Formatted: Font: Italic

Formatted: Font: Italic

303 molecule or condition that inhibits glutathione biosynthesis or the cellular glutathione-dependent  
304 antioxidant enzyme glutathione peroxidase 4 (GPX4) and results in an accumulation of ROS (Cao  
305 and Dixon 2016; Xie et al. 2016).

306 Experiments conducted with high glucose concentrations shows significant apoptotic  
307 death compared to normal medium in untreated cells however no change in cell count and ROS,  
308 because high glucose could activate apoptosis signaling pathway and down-regulation of anti-  
309 apoptotic proteins *BCL2*, *MAPK8*, and *MAPK10* (Vasu et al. 2013). However, only high glucose  
310 had less affect to cell count and level of ROS but when combine high glucose with FAC, and  
311 cytokines could lead to increase level of ROS. Hyperglycemic condition in the combination of  
312 FAC and cytokines induce production of ROS and lead to apoptosis and cause reducing of insulin  
313 in 1.1B4 cells that might be resulting from the down regulation of *INS* and other genes involved  
314 in insulin secretion, including *GCK*, *PSCK1*, and *PSCK2* (Vasu et al. 2014; Kooptiwut et al. 2005;  
315 Jonas et al. 2009; Laybutt et al. 2002). This might be due to the interference of high glucose that  
316 reduces the *PDX1*, an important gene involved in the secretory function (Sachdeva et al. 2009).  
317 The effect of cytokines on insulin production in hyperglycemia was found (Zhang and Kim 1995;  
318 Kiely et al. 2007). Moreover, it was found that glucose toxicity induced ROS production and  
319 activated the apoptosis signaling pathway (Robertson 2004). This information is concomitant with  
320 our study that the highest ROS, the lowest *INS* expression, and insulin secretion were found in  
321 FAC combined with IL-1 $\beta$  and TNF- $\alpha$  in high glucose level. This results could be supported the  
322 mechanism of insulin dependent or DM development in  $\beta$ -thalassemia patients who had iron  
323 overload and high level of cytokines IL-1 $\beta$  or TNF- $\alpha$ .

324 However, this study was performed only in human pancreatic  $\beta$ -cell line as a model  
325 which no direct measurement in humans and external validation but our previous data suggests

Formatted: Font: Italic

Formatted: Font: Italic

326 that in  $\beta$ -thalassemia/HbE patients with diabetes had high level of ROS, low level of glutathione,  
327 reduced the  $\beta$ -cell function (HOMAB) and insulin level decreased (Rattanaorn 2019 unpublished  
328 doctoral thesis). ▽

Deleted:

329

## 330 CONCLUSIONS

331 This study suggests that FAC combined with cytokines, IL-1 $\beta$  and TNF- $\alpha$  in high glucose  
332 condition could increase ROS production, ER stress and apoptosis induction. However, they  
333 reduce insulin secretion in human pancreatic  $\beta$ -cell lines. This information could be benefit for  
334 understanding the mechanism on development of DM in thalassemia patient.

335

## 336 ACKNOWLEDGEMENTS

337 We gratefully acknowledge Thalassemia Research Center, Institute of Molecular Bioscience and  
338 Faculty of Medical Technology, Mahidol University, Thailand.

339

## 340 ADDITIONAL INFORMATION AND DECLARATION

### 341 Funding

342 This study was supported by Mahidol University Research Grants, Research Chair Grant, [National](#)  
343 [Science and Technology Development Agency \(NSTDA\)](#), ▽ and the Office of the Higher Education  
344 Commission and Mahidol University under the National Research University Initiative .[Patchara](#)  
345 [Rattanaorn](#) was supported by the Thailand Graduate Institute of Science and Technology (TGIST), ▽  
346 NSTDA (grant number TG221457037D).

Deleted: (NSTD)

Deleted: R

Deleted: (

### 347 Competing interests

348 The authors declare that they have no competing interests

## REFERENCES

- Andrews, N. C. 1999. 'The iron transporter DMT1', *International Journal of Biochemistry and Cell Biology*, 31: 991-4.
- Berchtold, L. A., M. Prause, J. Storling, and T. Mandrup-Poulsen. 2016. 'Cytokines and Pancreatic beta-Cell Apoptosis', *Advances in Clinical Chemistry*, 75: 99-158.
- Bogdan, A. R., M. Miyazawa, K. Hashimoto, and Y. Tsuji. 2016. 'Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease', *Trends in Biochemical Sciences*, 41: 274-86.
- Cao, J. Y., and S. J. Dixon. 2016. 'Mechanisms of ferroptosis', *Cellular and Molecular Life Sciences*, 73: 2195-209.
- Dixon, S. J., and B. R. Stockwell. 2014. 'The role of iron and reactive oxygen species in cell death', *Nature Chemical Biology*, 10: 9-17.
- Doyard, M., N. Fatih, A. Monnier, M. L. Island, M. Aubry, P. Leroyer, R. Bouvet, G. Chales, J. Mosser, O. Loreal, and P. Guggenbuhl. 2012. 'Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells', *Osteoporosis International*, 23: 2435-45.
- Galanello, R., and R. Origa. 2010. 'Beta-thalassemia', *Orphanet Journal of Rare Diseases*, 5: 11.
- Ghergherehchi, R., and A. Habibzadeh. 2015. 'Insulin resistance and beta cell function in patients with beta-thalassemia major', *Hemoglobin*, 39: 69-73.
- Hansen, J. B., M. F. Tonnesen, A. N. Madsen, P. H. Hagedorn, J. Friberg, L. G. Grunnet, R. S. Heller, A. O. Nielsen, J. Storling, L. Baeyens, L. Anker-Kitai, K. Qvortrup, L. Bouwens, S. Efrat, M. Aalund, N. C. Andrews, N. Billestrup, A. E. Karlsen, B. Holst, F. Pociot, and T. Mandrup-Poulsen. 2012. 'Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic beta cell fate in response to cytokines', *Cell Metabolism*, 16: 449-61.
- Jonas, J. C., M. Bensellam, J. Duprez, H. Elouil, Y. Guiot, and S. M. Pascal. 2009. 'Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes', *Diabetes, Obesity & Metabolism*, 11 Suppl 4: 65-81.
- Ke, J. Y., W. J. Cen, X. Z. Zhou, Y. R. Li, W. D. Kong, and J. W. Jiang. 2017. 'Iron overload induces apoptosis of murine preosteoblast cells via ROS and inhibition of AKT pathway', *Oral Diseases*, 23: 784-94.

Formatted: Line spacing: 1.5 lines

Formatted: Thai Distributed Justification, Line spacing: 1.5 lines

384 Kiely, A., N. H. McClenaghan, P. R. Flatt, and P. Newsholme. 2007. 'Pro-inflammatory cytokines  
 385 increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a  
 386 clonal pancreatic beta-cell line', *Journal of Endocrinology*, 195: 113-23.

387 Koonyosying, P., C. Uthaipibull, S. Fucharoen, E. V. Koumoutsea, J. B. Porter, and S.  
 388 Srichairatanakool. 2019. 'Decrement in Cellular Iron and Reactive Oxygen Species, and  
 389 Improvement of Insulin Secretion in a Pancreatic Cell Line Using Green Tea Extract',  
 390 *Pancreas*, 48: 636-43.

391 Kooptiwut, S., M. Kebede, S. Zraika, S. Visinoni, K. Aston-Mourney, J. Favaloro, C. Tikellis, M.  
 392 C. Thomas, J. M. Forbes, M. E. Cooper, M. Dunlop, J. Proietto, and S. Andrikopoulos.  
 393 2005. 'High glucose-induced impairment in insulin secretion is associated with reduction  
 394 in islet glucokinase in a mouse model of susceptibility to islet dysfunction', *Journal of*  
 395 *Molecular Endocrinology*, 35: 39-48.

396 Laybutt, D. R., A. Sharma, D. C. Sgroi, J. Gaudet, S. Bonner-Weir, and G. C. Weir. 2002. 'Genetic  
 397 regulation of metabolic pathways in beta-cells disrupted by hyperglycemia', *Journal of*  
 398 *Biological Chemistry*, 277: 10912-21.

399 Li, M. J., S. S. Peng, M. Y. Lu, H. H. Chang, Y. L. Yang, S. T. Jou, D. T. Lin, and K. H. Lin.  
 400 2014. 'Diabetes mellitus in patients with thalassemia major', *Pediatric Blood & Cancer*,  
 401 61: 20-4.

402 Li, S. W., C. M. Liu, J. Guo, A. M. Marcondes, J. Deeg, X. Li, and F. Guan. 2016. 'Iron overload  
 403 induced by ferric ammonium citrate triggers reactive oxygen species-mediated apoptosis  
 404 via both extrinsic and intrinsic pathways in human hepatic cells', *Human and Experimental*  
 405 *Toxicology*, 35: 598-607.

406 Liang, Y., R. Bajoria, Y. Jiang, H. Su, H. Pan, N. Xia, R. Chatterjee, and Y. Lai. 2017. 'Prevalence  
 407 of diabetes mellitus in Chinese children with thalassaemia major', *Tropical Medicine and*  
 408 *International Health*, 22: 716-24.

409 Lu, W., M. Zhao, S. Rajbhandary, F. Xie, X. Chai, J. Mu, J. Meng, Y. Liu, Y. Jiang, X. Xu, and  
 410 A. Meng. 2013. 'Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal  
 411 stem cells in vitro and suppresses hematopoiesis in iron overload patients', *European*  
 412 *Journal of Haematology*, 91: 249-61.

413 McCluskey, J. T., M. Hamid, H. Guo-Parke, N. H. McClenaghan, R. Gomis, and P. R. Flatt. 2011.  
 414 'Development and functional characterization of insulin-releasing human pancreatic beta  
 415 cell lines produced by electrofusion', *Journal of Biological Chemistry*, 286: 21982-92.  
 416 Metwalley, K. A., and A. R. El-Saied. 2014. 'Glucose homeostasis in Egyptian children and  
 417 adolescents with beta-Thalassemia major: Relationship to oxidative stress', *Indian Journal  
 418 of Endocrinology and Metabolism*, 18: 333-9.  
 419 Noetzli, L. J., S. D. Mittelman, R. M. Watanabe, T. D. Coates, and J. C. Wood. 2012. 'Pancreatic  
 420 iron and glucose dysregulation in thalassemia major', *American Journal of Hematology*,  
 421 87: 155-60.  
 422 Rattanaorn P. 2019. Mechanism of diabetes mellitus in thalassemia. D. Phil. Thesis, Mahidol  
 423 University.  
 424 Pepe, A., A. Meloni, G. Rossi, V. Caruso, L. Cuccia, A. Spasiano, C. Gerardi, A. Zuccarelli, D.  
 425 G. D'Ascola, S. Grimaldi, M. Santodirocco, S. Campisi, M. E. Lai, B. Piraino, E. Chiodi,  
 426 C. Ascoti, L. Gulino, V. Positano, M. Lombardi, and M. R. Gamberini. 2013. 'Cardiac  
 427 complications and diabetes in thalassaemia major: a large historical multicentre study',  
 428 *British Journal of Haematology*, 163: 520-7.  
 429 Robertson, R. P. 2004. 'Chronic oxidative stress as a central mechanism for glucose toxicity in  
 430 pancreatic islet beta cells in diabetes', *Journal of Biological Chemistry*, 279: 42351-4.  
 431 Sachdeva, M. M., K. C. Claiborn, C. Khoo, J. Yang, D. N. Groff, R. G. Mirmira, and D. A. Stoffers.  
 432 2009. 'Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress',  
 433 *Proceedings of the National Academy of Sciences of the United States of America*, 106:  
 434 19090-5.  
 435 Tiedge, M., S. Lortz, J. Drinkgern, and S. Lenzen. 1997. 'Relation between antioxidant enzyme  
 436 gene expression and antioxidative defense status of insulin-producing cells', *Diabetes*, 46:  
 437 1733-42.  
 438 Vasu, S., N. H. McClenaghan, J. T. McCluskey, and P. R. Flatt. 2013. 'Cellular responses of novel  
 439 human pancreatic beta-cell line, 1.1B4 to hyperglycemia', *Islets*, 5: 170-7.  
 440 Vasu, S., N. H. McClenaghan, J. T. McCluskey, and P. R. Flatt. 2014. 'Mechanisms of toxicity by  
 441 proinflammatory cytokines in a novel human pancreatic beta cell line, 1.1B4', *Biochimica  
 442 et Biophysica Acta*, 1840: 136-45.

Deleted: \_\_\_\_\_

444 Wanachiwanawin, W., E. Wiener, U. Siripanyaphinyo, S. Chinprasertsuk, F. Mawas, S.  
 445 Fucharoen, S. N. Wickramasinghe, P. Pootrakul, and S. Visudhiphan. 1999. 'Serum levels  
 446 of tumor necrosis factor-alpha, interleukin-1, and interferon-gamma in beta(o)-  
 447 thalassemia/HbE and their clinical significance', *Journal of Interferon and Cytokine*  
 448 *Research*, 19: 105-11.

449 Wang, C., Y. Guan, and J. Yang. 2010. 'Cytokines in the Progression of Pancreatic beta-Cell  
 450 Dysfunction', *International Journal of Endocrinology*, 2010: 515136.

451 Wang, Y., R. Branicky, A. Noe, and S. Hekimi. 2018. 'Superoxide dismutases: Dual roles in  
 452 controlling ROS damage and regulating ROS signaling', *Journal of Cell Biology*, 217:  
 453 1915-28.

454 Weatherall, David. 2003. *Beginning: the molecular pathology of haemoglobin* (MPG Books:  
 455 Cornwall).

456 Xie, Y., W. Hou, X. Song, Y. Yu, J. Huang, X. Sun, R. Kang, and D. Tang. 2016. 'Ferroptosis:  
 457 process and function', *Cell Death and Differentiation*, 23: 369-79.

458 Yang, F., Y. Li, G. Yan, T. Liu, C. Feng, R. Gong, Y. Yuan, F. Ding, L. Zhang, E. Idiatullina, V.  
 459 Pavlov, Z. Han, W. Ma, Q. Huang, Y. Yu, Z. Bao, X. Wang, B. Hua, Z. Du, B. Cai, and L.  
 460 Yang. 2017. 'Inhibition of iron overload-induced apoptosis and necrosis of bone marrow  
 461 mesenchymal stem cells by melatonin', *Oncotarget*, 8: 31626-37.

462 Zhang, S., and K. H. Kim. 1995. 'TNF-alpha inhibits glucose-induced insulin secretion in a  
 463 pancreatic beta-cell line (INS-1)', *FEBS Letters*, 377: 237-9.

464

Formatted: Line spacing: 1.5 lines